Skip to main content

Main menu

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Archive
    • Subject Collections
    • Special Collections
  • Reviews & Opinions
    • Editorials
    • Found in Translation
    • Insights
    • People & Ideas
    • Perspectives
    • Reviews
    • Viewpoints
  • Alerts
  • About
    • History
    • Editors & Staff
    • Policies & Permissions
    • Advertise
    • Contact Us
    • Privacy Policy
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Publication Fees
    • Author Services
  • Subscriptions
  • Rockefeller University Press
  • JCB
  • JEM
  • JGP
  • LSA

User menu

  • Log in
  • Log out

Search

  • Advanced search
JEM
  • Rockefeller University Press
  • JCB
  • JEM
  • JGP
  • LSA
  • Log in
  • Log out
JEM

Advanced Search

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Archive
    • Subject Collections
    • Special Collections
  • Reviews & Opinions
    • Editorials
    • Found in Translation
    • Insights
    • People & Ideas
    • Perspectives
    • Reviews
    • Viewpoints
  • Alerts
  • About
    • History
    • Editors & Staff
    • Policies & Permissions
    • Advertise
    • Contact Us
    • Privacy Policy
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Publication Fees
    • Author Services
  • Subscriptions

You are here

jem Home » 2013 Archive » 23 September » 210 (10): 1919
Brief Definitive Report

CD4+ T cells are trigger and target of the glucocorticoid response that prevents lethal immunopathology in toxoplasma infection

David G. Kugler, Paul R. Mittelstadt, Jonathan D. Ashwell, Alan Sher, Dragana Jankovic
David G. Kugler
Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases; Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute; and The Johns Hopkins University/National Institutes of Health Graduate Partnership Program; National Institutes of Health, Bethesda, MD 20892Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases; Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute; and The Johns Hopkins University/National Institutes of Health Graduate Partnership Program; National Institutes of Health, Bethesda, MD 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul R. Mittelstadt
Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases; Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute; and The Johns Hopkins University/National Institutes of Health Graduate Partnership Program; National Institutes of Health, Bethesda, MD 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan D. Ashwell
Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases; Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute; and The Johns Hopkins University/National Institutes of Health Graduate Partnership Program; National Institutes of Health, Bethesda, MD 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Sher
Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases; Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute; and The Johns Hopkins University/National Institutes of Health Graduate Partnership Program; National Institutes of Health, Bethesda, MD 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dragana Jankovic
Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases; Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute; and The Johns Hopkins University/National Institutes of Health Graduate Partnership Program; National Institutes of Health, Bethesda, MD 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1084/jem.20122300 | Published August 26, 2013
  • Article
  • Figures & Data
  • Info
  • Metrics
  • Preview PDF
Loading

Abstract

Synthetic glucocorticoids (GCs) are commonly used in the treatment of inflammatory diseases, but the role of endogenous GCs in the regulation of host-protective immune responses is poorly understood. Here we show that GCs are induced during acute Toxoplasma gondii infection and directly control the T cell response to the parasite. When infected with toxoplasma, mice that selectively lack GC receptor (GR) expression in T cells (GRlck-Cre) rapidly succumb to infection despite displaying parasite burdens indistinguishable from control animals and unaltered levels of the innate cytokines IL-12 and IL-27. Mortality in the GRlck-Cre mice was associated with immunopathology and hyperactive Th1 cell function as revealed by enhanced IFN-γ and TNF production in vivo. Unexpectedly, these CD4+ T lymphocytes also overexpressed IL-10. Importantly, CD4+ T cell depletion in wild-type or GRlck-Cre mice led to ablation of the GC response to infection. Moreover, in toxoplasma-infected RAG−/− animals, adoptive transfer of CD4+ T lymphocytes was required for GC induction. These findings establish a novel IL-10–independent immunomodulatory circuit in which CD4+ T cells trigger a GC response that in turn dampens their own effector function. In the case of T. gondii infection, this self-regulatory pathway is critical for preventing collateral tissue damage and promoting host survival.

The protective antimicrobial immune response, in addition to generating appropriate effector functions, must also incorporate mechanisms for self-regulation to prevent bystander damage to host tissue. Several mechanisms have been identified that participate in effector CD4 T cell regulation. These are thought to be mediated primarily by immunosuppressive cytokines and/or inhibitory surface molecules (Bluestone, 2011).

An excellent example of host-protective negative regulation of CD4 T cell function occurs during the Th1 response to Toxoplasma gondii, an intracellular protozoan parasite. This IL-12–driven response results in production of high levels of IFN-γ and TNF that efficiently control parasite replication in both hematopoietic and nonhematopoietic cells (Yap and Sher, 1999). Nevertheless, the exuberant cytokine production occurring during T. gondii infection can also be host-detrimental, an outcome first documented in acutely infected IL-10−/− mice that while successfully controlling parasite growth succumb to cytokine storm–mediated immunopathology (Gazzinelli et al., 1996). Subsequent studies have revealed similar pathological sequelae in T. gondii–infected IL-27R−/− animals (Villarino et al., 2003) and in chronically infected mice deficient in 5-lipoxygenase (Aliberti et al., 2002). The common feature of these three genetic deficiencies is that each leads to uncontrolled Th1-type responses. IL-10 and lipoxin A4 act directly on APCs to suppress IL-12 secretion, whereas IL-27 acts primarily on CD4+ T cells by promoting their IL-10 expression and at the same time suppressing other components of T cell activation (Hunter and Kastelein, 2012). Importantly, these three regulatory circuits originally described in T. gondii infection have now been documented in several parasitic, viral, and bacterial experimental models (Jankovic et al., 2010; Cyktor and Turner, 2011).

In the present study, we identify the endogenous glucocorticoid (GC) response as an additional pathway that plays a critical role in regulating CD4 T cell effector function during T. gondii infection. GCs are steroid hormones driven by the hypothalamic-pituitary-adrenal axis that are known to exert pleiotropic effects on immune cells and are frequently induced in response to infection (Sternberg, 2006; Jamieson et al., 2010; Pérez et al., 2011). Here, we demonstrate that CD4 T lymphocytes are both the target and trigger of the T. gondii–induced GC response. This pathway of self-regulation appears to play a critical role in host resistance by preventing the pathological consequences of Th1 hyperresponsiveness.

RESULTS AND DISCUSSION

GC receptor (GR) signaling in T cells is required for host survival during acute T. gondii infection

Although able to control infection, WT mice inoculated with nonlethal T. gondii strains undergo transient weight loss and display a hunched and scruffy appearance suggestive of a GC-mediated stress response. To determine whether toxoplasma infection triggers GC production, we measured corticosterone by ELISA in the sera of C57BL/6 mice challenged i.p. with cysts of the ME49 strain while simultaneously assaying IL-12, IFN-γ, IL-10, and IL-27. Serum GC levels increased sixfold during acute infection with kinetics that closely resembled those determined for the antiinflammatory (IL-10 and IL-27) as opposed to proinflammatory (IL-12 and IFN-γ) cytokines (Fig. 1 A). Thus, whereas IL-12 (p40 and p70) and IFN-γ reached peak levels on days 5 and 6 after infection, respectively, GCs together with IL-10 and IL-27 displayed minor increases at these time points and did not peak until day 8.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

T. gondii infection elicits a GC response, and the lack of GR signaling in T cells results in acute mortality of toxoplasma-infected mice. (A) C57BL/6 mice were infected i.p. with an average of 15 ME49 cysts, and serum corticosterone, IFN-γ, IL-12p70 and p40, IL-27p28, and IL-10 levels were measured on the days indicated. Symbols represent mean ± SEM of the ELISA values for the individual animals (n = 3–12) at each time point pooled from three independent experiments. (B) Survival of homozygote GRlck-Cre, heterozygote GRfl/+lck-Cre, and littermate control animals after infection. The survival curves shown are from one representative of 10 experiments performed, two of which included GRfl/+lck-Cre mice. (C) Parasite burdens in PECs and spleen on day 8 after infection as determined by plaque assay. Bars represent mean ± SEM number of PFU per organ (n = 3–5 mice). (D) Weight loss and serum levels of AST and CK in infected animals. Results shown are means ± SEM for values for the individual mice (n = 4–5). No distinguishing histopathological changes were detected in lung, heart, liver, and kidney at this day 8 time point. Data presented in C–E are representative of two experiments performed. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

Because GCs promote IL-10 production by T cells (Barrat et al., 2002) and dampen IFN-γ production by Th1 lymphocytes (Franchimont et al., 2000; Liberman et al., 2007), we asked whether GCs exert a similar regulatory role during T. gondii infection by acting on T cells. To this end, we infected mice that selectively lack GR expression in T cells (GRlck-Cre; Mittelstadt et al., 2012). In contrast to littermate control animals, GRlck-Cre mice rapidly succumbed during the acute phase of infection with similar kinetics to those previously described for both IL-10−/− and IL-27R−/− T. gondii–infected animals (Fig. 1 B). Interestingly, mice heterozygous for GR deletion (GRfl/+lck-Cre) displayed the same mortality as homozygous-deficient animals (Fig. 1 B), consistent with prior findings (Wüst et al., 2008; Mittelstadt et al., 2012), arguing for a threshold requirement in GR signaling in T cells. Together these results demonstrate that T. gondii infection triggers GC production and that this response plays a critical and nonredundant T cell–dependent host-protective function.

T. gondii–infected GRlck-Cre mice display evidence of enhanced tissue pathology despite unaltered parasite burdens

To determine whether the increased mortality in T. gondii–exposed GRlck-Cre mice is caused by an ineffective immune response, we measured parasite burdens on day 8 after infection. Despite their distinct survival outcomes, GRlck-Cre and control animals displayed indistinguishable frequencies of infected cells (not depicted), as well as total numbers of parasites in peritoneum (the site of infection; peritoneum exudate cells [PECs]) and spleen (Fig. 1 C). Instead, the rapid mortality of infected GRlck-Cre (and heterozygous GRfl/+lck-Cre) mice was preceded by enhanced weight loss and increased levels of serum aspartate aminotransferase (AST) and creatine kinase (CK), major biomarkers for hepatic dysfunction and muscle damage, respectively (Fig. 1 D).

GRlck-Cre mice infected with T. gondii exhibit a cytokine expression profile distinct from IL-10−/− and IL-27R−/− animals

The phenotype observed for GRlck-Cre animals was reminiscent of that previously described in T. gondii–infected IL-10−/− and IL-27R−/− mice, which display increased levels of serum IL-12p40 and IFN-γ as a result of their deficiencies in IL-10 production. Because in our model GR deletion is restricted to T cells, an effect on innate cytokine production by APCs seemed unlikely. Nevertheless, lack of GR expression in T cells could indirectly cause increased IL-12p40 if GC signaling is required for IL-10 production by CD4+ T lymphocytes. However, levels of IL-12p40 or p70 and IL-27p28 in serum and peritoneum were indistinguishable between control and GRlck-Cre animals (Fig. 2, A–C), a finding inconsistent with either altered APC function or defective IL-10 production.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

T. gondii–infected GRlck-Cre mice display enhanced IFN-γ, TNF, and IL-10 production, despite normal levels of innate cytokines and CD4+ T cell numbers. (A–F) WT and GRlck-Cre littermates were infected i.p. with 15 ME49 cysts, and serum IL-12p40 (A), IL-12p70 (B), IL-27p28 (C), IFN-γ (D), TNF (E), and IL-10 (F) were measured on the days indicated as well as cytokine levels in peritoneal exudates on day 8 or 4 in the case of IL-12p70 (bar graphs). Each symbol or bar represents mean ± SEM of values for individual animals (n = 3–22). (G and H) Kinetics of total numbers of CD4+ and CD8+ T cells in PECs (G) or spleen (H) in T. gondii–infected animals. Bars represent mean ± SEM of values for individual animals (n = 3–28 per time point). Data presented are pooled from 10 independent experiments performed. *, P < 0.05; ***, P < 0.001.

In contrast to IL-12 and IL-27, dramatic increases in IFN-γ levels were observed in the same infected GRlck-Cre mice. Although the initial phase of the response (before day 5) was similar to that seen in WT animals, on days 7–8 after infection, when GC levels peak and IFN-γ levels are decreasing in WT mice, GRlck-Cre animals exhibited an uncontrolled increase in the cytokine (Fig. 2 D). Interestingly, infected GRlck-Cre animals also displayed a dramatic elevation in TNF and IL-10 (Fig. 2, E and F), a phenotype clearly distinct from that of infected IL-10– or IL-27R–deficient mice. Moreover, the delayed onset and combined overexpression of IFN-γ, TNF, and IL-10, which are known Th1 products, support the concept that the defective host resistance in GRlck-Cre mice results from a perturbation of the adaptive, rather than innate, immune system.

Th1 cells from T. gondii–infected GRlck-Cre mice display hyperactivity in vivo but not in vitro

The increased production of IFN-γ, TNF, and IL-10 in GRlck-Cre mice could result from either the expansion of activated T cells or the enhanced responsiveness of cells within an unchanged pool size. Although the first hypothesis is consistent with the known role of GC in T cell apoptosis (Sionov et al., 2006), no significant increases were observed in the total number of CD4+ and CD8+ T lymphocytes (Fig. 2, G and H) in GRlck-Cre versus control mice during acute infection. In addition, no differences were detected in the frequencies of Ki-67+ versus Annexin-V+ T cells in the two mouse strains (not depicted).

To test the second possibility, spleen cells isolated from GRlck-Cre and WT mice on day 8 after infection were stimulated in vitro with either anti-CD3 mAb or the MHC class II–restricted parasite peptide AS15 (Grover et al., 2012). No differences were observed in IFN-γ or IL-10 responses (not depicted). Moreover, frequencies of IFN-γ+–producing cells, which at this time point are restricted to the CD4+ CD44+ T-bet+ Foxp3− population (Jankovic et al., 2007), were comparable between GRlck-Cre and WT animals (Fig. 3, A–C).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

GCs regulate the magnitude of the Th1 response in vivo in T. gondii–infected mice. (A) WT and GRlck-Cre mice were infected i.p. with 15 ME49 cysts, and frequencies of IFN-γ+ CD4+ CD44+ T cells were determined on day 8 in splenocytes stimulated in vitro by plate-bound anti-CD3 mAb. Bars represent mean ± SEM of values for individual animals (n = 5–11) determined by ICS. (B–E) Bulk splenocytes, described in A, were stimulated in vitro with AS15 peptide alone (B and C) or in the presence of Dex (D and E), and frequencies of IFN-γ+ and TNF+ cells were assayed by ICS. (B and D) The dot plots shown were gated on CD44+ CD4+ T cells. (C) Bars represent mean ± SEM of values determined from cultures of individual animals (n = 5) shown in B. In E, each symbol indicates the ratio of cytokine MFI for IFN-γ+ TNF+ CD4+ T cells determined by ICS in parallel cultures from individual mice (n = 5) stimulated with AS15 peptide in the presence versus absence of Dex (shown in D and B). (F) Numbers of AS15 tetramer+ CD4+ T cells in spleen on day 8 after infection. Bars represent mean ± SEM of values for individual animals (n = 13–16). (G and H) Day 8 toxoplasma-infected mice were injected i.v. with AS15 peptide, and 6 h later, frequencies of IFN-γ+ tetramer+ cells were determined by ICS in splenocytes prepared from individual mice. The dot plots shown were gated on CD44+ CD4+ T cells (G), and bars represent mean ± SEM of values for individual mice (n = 6; H). (I and J) Uninfected WT and day 8 infected mice were injected i.p. with BFA and ICS was performed. (I) The representative dot plots shown are gated on CD44+ CD4+ T lymphocytes. (J) Bars represent mean ± SEM of frequencies of IFN-γ+ CD44+ CD4+ T cells for individual mice (n = 5), whereas symbols indicate IFN-γ MFI values for CD44+ CD4+ T cells from one mouse. The experiments shown in A–J are representative of two to four performed. (K) Ifng, Tnf, and Il10 mRNA expression in CD4+ CD44+ T cells purified from peritonea of day 8 infected mice (n = 3–5). Bars represent mean ± SEM of cytokine expression relative to Hprt from three independent experiments. AU, arbitrary units. *, P < 0.05; **, P < 0.01.

Although CD4+ T lymphocytes from both groups displayed indistinguishable cytokine responsiveness in vitro, their behavior in vivo was clearly distinct. Whereas the T. gondii–specific CD4+ T population recognized by the AS15 tetramer (Grover et al., 2012) expanded equally in GRlck-Cre and control mice (Fig. 3 F), after injection of AS15 peptide i.v. on day 8 of infection, significantly higher frequencies of Th1 cells producing IFN-γ were detected in GRlck-Cre animals (Fig. 3, G and H). To extend this in vivo analysis to a broader range of T cell specificities, we next analyzed infected mice injected i.p. with brefeldin A (BFA). We found that CD44+ T-bet+ Foxp3− cells in PECs represent 79% versus 80% of CD4 T lymphocytes in control and GRlck-Cre-infected animals, respectively. Nevertheless, the frequency of IFN-γ–producing cells was significantly higher in GRlck-Cre mice as was their overall IFN-γ mean fluorescence intensity (MFI; Fig. 3, I and J). In addition, increased levels of Ifng and Tnf as well as Il10 mRNA were detected by RT-PCR in FACS-sorted PEC CD4+ CD44+ T lymphocytes from GRlck-Cre versus control animals (Fig. 3 K). However, no differences in expression of the co-stimulatory molecules CD28, CD69, ICOS, and GITR, as well as cytokine receptors CD25, CD119, and CD127 were detected in the same populations (not depicted).

Together these experiments demonstrated that despite similar antigen (Ag) load and comparable innate cytokine milieu, Th1 effectors in T. gondii–infected GRlck-Cre animals respond more vigorously to Ag stimulation than the equivalent cell population in WT mice. However, when removed from GC pressure by in vitro culture, cells from both groups exhibited equal responsiveness. When GC pressure was reintroduced in vitro by addition of dexamethasone (Dex), cytokine production by Th1 cells from infected WT, but not GRlck-Cre, mice was suppressed (not depicted). Interestingly, in WT cultures stimulated with AS15 peptide in the presence of Dex, the frequency of responding CD4+ T cells remained unchanged (Fig. 3, B vs. D), but their MFIs for IFN-γ+ and TNF+ were reduced (Fig. 3 E).

CD4 T lymphocytes drive mortality in T. gondii–infected GRlck-Cre mice

The above experiments suggest that Th1 cells are a major target of GC-mediated suppression during toxoplasma infection. In support of this hypothesis, anti-CD4, but not anti-CD8, mAb treatment attenuated acute mortality in GRlck-Cre mice (Fig. 4 A). Importantly, CD4 T cell depletion also prevented the increase in pathological markers observed in the latter group (Fig. 4 B). As predicted (Jankovic et al., 2007), although serum IL-12p40 levels were similarly increased, the systemic IFN-γ and IL-10 responses in sera of CD4-depleted T. gondii–infected mice were reduced to a comparable level in both GRlck-Cre and WT animals (Fig. 4 C). To directly test the pathological role of CD4+ T lymphocytes lacking GR, we reconstituted RAG KO mice with either WT or GRlck-Cre CD4+ T cells from naive mice. In agreement with the depletion experiments, all RAG KO animals that received GRlck-Cre CD4+ T lymphocytes succumbed to infection, whereas the majority of recipients of WT cells survived (Fig. 4 D). Moreover, serum levels of IFN-γ, alanine aminotransferase (ALT), and AST were significantly higher in mice reconstituted with GRlck-Cre versus WT cells (IFN-γ: 11.6 ± 1.5 vs. 7.2 ± 1.0; ALT: 353 ± 73 vs. 162 ± 28; AST: 662 ± 122 vs. 310 ± 46).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Mortality in T. gondii–infected GRlck-Cre mice is dependent on CD4+ T cells that also drive the induction of the GC response. (A–C) T. gondii–infected mice were treated i.p. with anti-CD4, anti-CD8, or control mAb on days −1, 3, 5, 8, and 12 (n = 3–5 mice). Survival was monitored daily (A), and serum levels of AST and CK (B) and IL-12p40, IFN-γ, and IL-10 (C) were measured on day 8. Bars represent mean ± SEM of values for individual animals (n = 3–12). (D) Survival of T. gondii–infected RAG KO mice (n = 4) and those adoptively transferred with naive GRlck-Cre (n = 6) or WT (n = 9) CD4+ T cells. (E) Serum corticosterone levels in animals described in A. The results shown in A–E are representative of three experiments performed. (F–H) Serum corticosterone levels in naive and toxoplasma-infected mice deficient in the genes indicated (F), WT animals treated with anti-TNF and anti–IFN-γ Ab alone or in combination with anti–IL-6 Ab (G), and RAG−/− and OT-II RAG−/− mice (H). Bars represent mean ± SEM of the ELISA values for individual mice (n = 4–10) pooled from two independent experiments. (I) Corticosterone levels in uninfected and 8-d T. gondii–infected RAG−/− animals, one group of which received naive WT CD4+ T cells. Bars represent mean ± SEM of ELISA values for individual mice (n = 5–8) from one representative out of three performed. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

The GC response in T. gondii infection is triggered by CD4 T lymphocytes

The above results demonstrated that the GC response induced during the acute phase of infection plays an essential host-protective role by modulating the responsiveness of CD4 T lymphocytes. Because the interaction between the endocrine and immune system is known to be bidirectional, we next tested whether depletion of CD4+ T cells might influence GC production during toxoplasma infection. Unexpectedly, serum GC levels were dramatically reduced in infected mice depleted of CD4+, but not CD8+, T cells (Fig. 4 E). In contrast, GC responses were not compromised in toxoplasma-infected mice lacking the signaling molecules MyD88, IFN-γR, or IL-27R and cytokines TNF, IL-12p40, or IL-10 that are associated with both Th1 responses and have been previously implicated in driving GC responses (Fig. 4 F). Moreover, antibody (Ab) neutralization of IFN-γ, TNF, and IL-6 failed to inhibit the GC response in infected WT mice (Fig. 4 G).

Consistent with the depletion studies, RAG−/− mice failed to display significant increases in GC levels after toxoplasma infection (Fig. 4 H). In addition, serum GC levels remain unchanged in infected OT-II Tg RAG−/− mice that possess only OVA-specific CD4+ T cells (Fig. 4 H). However, RAG-deficient mice reconstituted with polyclonal WT CD4+ T cells showed a full restoration of GC levels, confirming that CD4 T lymphocytes recognizing parasite and/or self-Ags are necessary and sufficient to drive the GC response during acute T. gondii infection (Fig. 4 I).

GCs have multiple and sometimes opposing effects on T lymphocytes. They promote apoptosis but can also induce IL-7R expression and inhibit synthesis of some while enhancing production of other cytokines (Ashwell et al., 2000). In GRlck-Cre mice, the GR is deleted at the stage of double-negative thymocytes. As a consequence of thymic selection in the absence of GC influence, GRlck-Cre mice display blunted responses after immunization with soluble Ag (Mittelstadt et al., 2012). One would therefore predict that GRlck-Cre animals would be unable to control T. gondii infection. However, GRlck-Cre mice mount a highly effective Th1 immune response against the parasite and, indeed, are hyperresponsive. Thus, challenge with an antigenically complex intracellular pathogen, and the strong proinflammatory response that it induces, appears to completely reverse the immunocompromised state of GRlck-Cre mice. The nonbiased overproduction in GRlck-Cre mice of IFN-γ, TNF, and IL-10, three distinct cytokines secreted by Th1 cells, suggests that in T. gondii infection GCs function as a general damper of TCR signaling.

Based on these observations, we propose that the same phenomenon of decreased Ag threshold for TCR activation in the absence of GC signaling, which during thymocyte maturation drives the appearance of hyporeactive T cells, paradoxically, also underlies the hyperreactivity of Th1 cells in vivo during T. gondii infection. Although it is as yet unclear whether GR is a component of the TCR complex (Löwenberg et al., 2007), the blunted TCR response occurring in WT Th1 cells is consistent with the known inhibitory effects of GCs on AP-1, NF-κB, and NFAT (Ashwell et al., 2000). Superimposed on this mechanism may be additional suppressive effects of GCs on the STAT4 and/or T-bet signaling pathways (Franchimont et al., 2000; Liberman et al., 2007).

Although the induction of GCs has been previously observed in a variety of viral, bacterial, and parasitic infections, the signals responsible for triggering this response are poorly defined. Cytokines, and in particular IL-1, have been shown to be potent inducers of GC production, arguing for a strong association with the innate immune system (Sternberg, 2006). Nevertheless, the IL-1 pathway is not involved in the T. gondii system described here as infected MyD88−/− mice display an uncompromised GC response. Instead, our depletion and adoptive transfer experiments clearly implicate CD4 T lymphocytes themselves as drivers of GC production. Although CD4+ T cell–derived cytokines are obvious candidate mediators, our current findings argue against the role of IFN-γ, TNF, and IL-10. Nevertheless, the involvement of other soluble T cell products has not been ruled out. Alternatively, as a stress response, GC production in T. gondii infection could be the indirect result of CD4+ T cell–mediated tissue damage (Jamieson et al., 2010).

The findings reported here establish GC signaling as a fourth major pathway (along with IL-10, IL-27, and lipoxin production) for dampening the Th1 response during T. gondii infection to protect the host against lethal immunopathology. Such a multitargeted regulatory mechanism may be necessary to adequately brake the Th1 pathway, which also incorporates a positive feedback-loop through IFN-γ production (Lugo-Villarino et al., 2003; Schulz et al., 2009). In turn, each of these circuits represents a potential target for exploitation by the parasite in enhancing its virulence and/or promoting its own survival (Butcher et al., 2005; Bradley and Sibley, 2007). In this regard, it is of interest that the virulence of avian influenza virus has been associated with induction of the endogenous GC response (Tian et al., 2012).

MATERIALS AND METHODS

Experimental animals.

C57BL/6 mice were purchased from Taconic, and IL-10−/−, IL-12p40−/−, and RAG OT-II animals were obtained from the National Institute of Allergy and Infectious Diseases (NIAID) contract facility maintained by the same supplier. IFNγR−/−, TNF−/− (The Jackson Laboratory), IL-27R−/− (TCCR−/−; Chen et al., 2000), MyD88−/− (Adachi et al., 1998), GRlck-Cre, and GRfl/+lck-Cre (Mittelstadt et al., 2012) mice were bred and housed in our facilities. All animals were maintained at an American Association for the Accreditation of Laboratory Animal Care–accredited and specific pathogen–free facility at the NIAID/National Institutes of Health (NIH) or the National Cancer Institute/NIH. All procedures were performed in accordance with the protocols outlined in the Guide for the Care and Use of Laboratory Animals and described in an animal study proposal approved by the NIAID Animal Care and Use Committee. Age- and sex-matched GRlck-Cre and littermate control mice were used in all experiments.

T. gondii infection and determination of parasite burden.

Type II avirulent strain ME49 cysts were obtained from the brains of chronically infected C57BL/6 mice. Cyst preparations were pepsin treated to eliminate potential contamination with host cells and mice were inoculated i.p. with an average of 15 cysts. Parasite burden was assessed in PECs and spleen tissues by plaque assay that quantitates live parasites (Roos et al., 1994).

In vivo mAb treatment.

To deplete CD4 or CD8 T cells, mice were injected i.p. with 250 µg mAb on days −1, 2, 5, 8, and 12 with either anti-CD4 (GK1.5) or anti-CD8 (2.43), respectively. FACS analysis on blood samples from the treated animals performed with a noncompeting mAb (anti-CD4 [RM4-4] and anti-CD8 [53-6.7]) confirmed a >90% depletion of the targeted population. To block TNF, IFN-γ, or IL-6, mice were injected i.p. with 1 mg of neutralizing Ab XT3-11, XMG-1.2, or MP5-20F3 (Bio X Cell) on days −1, 1, 3, 5, and 7. Control groups of animals received an equivalent amount of rat mAb GL113.

In vivo cytokine response.

On day 8 after infection, mice were injected i.p. with BFA (Sigma-Aldrich; 250 µg/0.5 ml PBS; Liu and Whitton, 2005) or i.v. with the T. gondii–specific AS15 peptide (25 µg/0.2 ml PBS). In both cases, mice were euthanized 6 h later, and cell isolation and all subsequent steps of FACS staining were performed in BFA-containing medium until samples were fixed with 2% paraformaldehyde.

Body weight and hepatic enzyme measurements.

Individual mice were weighed before and each day after infection, and the percent change in body weight was calculated for each animal. Serum levels of AST and CK were determined using a commercial kit (Boehringer Ingelheim) in an automatic analyzer (model 917; Hitachi).

Cytokine ELISA and corticosterone measurements.

Serum samples were collected between 8:30–9:30 a.m. the day before or on indicated days after toxoplasma infection. Peritoneal lavage was performed with 3 ml PBS, cells were spun, and supernatants were stored. Levels of IL-12p40, IL-12p70, IL-27p28, IFN-γ, IL-10, TNF, and IL-10 were assayed using commercial ELISA kits (BD or R&D Systems). Serum corticosterone levels were measured by an EIA ELISA (Enzo Life Sciences).

Cell preparation and culture conditions.

Single-cell suspensions were prepared from PECs or spleens from individual naive and infected animals. Cells (1–2 × 106/ml) were cultured in 24-well plates in RPMI complete medium alone or in the presence of plate-bound anti-CD3 mAb (Jankovic et al., 2007) or 5 µg/ml AS15 peptide for 1 h before the addition of 10 µg/ml BFA. After an additional 5–6 h of incubation time, cells from each well were harvested and intracellular cytokine staining (ICS) was performed. Where indicated, 100 nM Dex (Sigma-Aldrich) was added to the cultures stimulated with anti-CD3 mAb or AS15 peptide.

Cell purification for adoptive transfer.

CD4+ T cells were isolated from spleens and lymph nodes by negative selection (Miltenyi Biotec) from either naive WT or GRlck-Cre mice. For adoptive transfer, RAG recipient received 10 × 106 CD4+ T cells i.v. (Jankovic et al., 2007).

Flow cytometry and ICS.

Splenocytes and PEC samples from individual animals were stained with Fixable Viability Dye (eBioscience), and an appropriate combination of mAbs specific for CD4 (RM4-5), CD8 (53–6.7), CD44 (IM7), TCRβ (H57-597), T-bet (O4-46), Foxp3 (MF23), IFN-γ (XMG1.2), TNF (MP6-XT22), or IL-10 (JES5-16E3) was purchased from eBioscience, BioLegend, or BD. Parasite-specific CD4+ T cells were determined by fluorescently labeled MHC class II tetramer bound to T. gondii antigenic peptide AS15 (Grover et al., 2012) provided by the NIH Tetramer Core Facility. Analysis of intracellular cytokine expression and Foxp3/T-bet staining were performed after cells were fixed and permeabilized using Perm-Fix solution (eBioscience). All samples were acquired on a LSR Fortessa flow cytometer (BD), and data were analyzed with FlowJo software (Tree Star).

Cell sorting.

Activated CD44+ CD62L− CD4+ T lymphocytes were isolated from pooled peritonea from day 8 infected mice (n = 3–5) stained with mAbs specific for CD4 (RM4-5), CD8 (53-6.7), CD44 (IM7), CD62L (MEL-14), I-A/I-E (M5/114.15.2), and B220 (RA-6B2) by sorting on a FACSAria III (BD).

Quantitative RT-PCR.

Total RNA was isolated (RNeasy Mini kit; QIAGEN) and reverse transcribed (SuperScript II Reverse transcription; Invitrogen). Gene expression analysis was performed using SYBR Green–based real-time quantitative PCR on an ABI Prism 7900HT analyzer (Applied Biosystems). Arbitrary units represent the ratio of cytokine mRNA levels compared with hypoxanthine guanine phosphoribosyltransferase (HPRT) mRNA levels. The following primer pairs were used: Hprt, 5′-AGCCTAAGATGAGCGCAAGT-3′ (forward) and 5′-TTACTAGGCAGATGGCCACA-3′ (reverse); Ifng, 5′-ATGAACGCTACACACTGCATC-3′ (forward) and 5′-CCATCCTTTTGCCAGTTCCTC-3′ (reverse); Tnf, 5′-GCCTCTTCTCATTCCTGCTTGT-3′ (forward) and 5′-GGCCATTTGGGAACTTCTCAT-3′ (reverse); and Il10, 5′-GCTCTTACTGACTGGCATGAG-3′ (forward) and 5′-CGCAGCTCTAGGAGCATGTG-3′ (reverse).

Statistical analysis.

The statistical significance of differences between data means was evaluated using a paired, two-tailed Student’s t test.

Acknowledgments

We thank Calvin Eigsti for performing FACS sorting. We also thank Drs. Carl G. Feng and Daniel L. Barber for invaluable discussions and Drs. Jacques Peschon and Carl G. Feng for critical reading of the manuscript.

This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and in part by an Intramural AIDS Research Fellowship (to D.G. Kugler).

The authors have no conflicting financial interests.

Footnotes

  • Abbreviations used:
    Ab
    antibody
    Ag
    antigen
    AST
    aspartate aminotransferase
    BFA
    brefeldin A
    CK
    creatine kinase
    Dex
    dexamethasone
    GC
    glucocorticoid
    GR
    GC receptor
    HPRT
    hypoxanthine guanine phosphoribosyltransferase
    ICS
    intracellular cytokine staining
    MFI
    mean fluorescence intensity
    PEC
    peritoneum exudate cell

  • Submitted: 11 October 2012
  • Accepted: 1 August 2013

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

References

  1. ↵
    1. O. Adachi,
    2. T. Kawai,
    3. K. Takeda,
    4. M. Matsumoto,
    5. H. Tsutsui,
    6. M. Sakagami,
    7. K. Nakanishi,
    8. S. Akira
    . 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity. 9:143–150. doi:10.1016/S1074-7613(00)80596-8
    OpenUrlCrossRefPubMed
  2. ↵
    1. J. Aliberti,
    2. C. Serhan,
    3. A. Sher
    . 2002. Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J. Exp. Med. 196:1253–1262. doi:10.1084/jem.20021183
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. J.D. Ashwell,
    2. F.W. Lu,
    3. M.S. Vacchio
    . 2000. Glucocorticoids in T cell development and function. Annu. Rev. Immunol. 18:309–345. doi:10.1146/annurev.immunol.18.1.309
    OpenUrlCrossRefPubMed
  4. ↵
    1. F.J. Barrat,
    2. D.J. Cua,
    3. A. Boonstra,
    4. D.F. Richards,
    5. C. Crain,
    6. H.F. Savelkoul,
    7. R. de Waal-Malefyt,
    8. R.L. Coffman,
    9. C.M. Hawrylowicz,
    10. A. O’Garra
    . 2002. In vitro generation of interleukin 10–producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)– and Th2-inducing cytokines. J. Exp. Med. 195:603–616. doi:10.1084/jem.20011629
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. J.A. Bluestone
    2011. Mechanisms of tolerance. Immunol. Rev. 241:5–19. doi:10.1111/j.1600-065X.2011.01019.x
    OpenUrlCrossRefPubMed
  6. ↵
    1. P.J. Bradley,
    2. L.D. Sibley
    . 2007. Rhoptries: an arsenal of secreted virulence factors. Curr. Opin. Microbiol. 10:582–587. doi:10.1016/j.mib.2007.09.013
    OpenUrlCrossRefPubMed
  7. ↵
    1. B.A. Butcher,
    2. L. Kim,
    3. A.D. Panopoulos,
    4. S.S. Watowich,
    5. P.J. Murray,
    6. E.Y. Denkers
    . 2005. IL-10-independent STAT3 activation by Toxoplasma gondii mediates suppression of IL-12 and TNF-α in host macrophages. J. Immunol. 174:3148–3152.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Q. Chen,
    2. N. Ghilardi,
    3. H. Wang,
    4. T. Baker,
    5. M.H. Xie,
    6. A. Gurney,
    7. I.S. Grewal,
    8. F.J. de Sauvage
    . 2000. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature. 407:916–920. doi:10.1038/35038103
    OpenUrlCrossRefPubMed
  9. ↵
    1. J.C. Cyktor,
    2. J. Turner
    . 2011. Interleukin-10 and immunity against prokaryotic and eukaryotic intracellular pathogens. Infect. Immun. 79:2964–2973. doi:10.1128/IAI.00047-11
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. D. Franchimont,
    2. J. Galon,
    3. M. Gadina,
    4. R. Visconti,
    5. Y. Zhou,
    6. M. Aringer,
    7. D.M. Frucht,
    8. G.P. Chrousos,
    9. J.J. O’Shea
    . 2000. Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J. Immunol. 164:1768–1774.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. R.T. Gazzinelli,
    2. M. Wysocka,
    3. S. Hieny,
    4. T. Scharton-Kersten,
    5. A. Cheever,
    6. R. Kühn,
    7. W. Müller,
    8. G. Trinchieri,
    9. A. Sher
    . 1996. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-γ and TNF-α. J. Immunol. 157:798–805.
    OpenUrlAbstract
  12. ↵
    1. H.S. Grover,
    2. N. Blanchard,
    3. F. Gonzalez,
    4. S. Chan,
    5. E.A. Robey,
    6. N. Shastri
    . 2012. The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden. Infect. Immun. 80:3279–3288. doi:10.1128/IAI.00425-12
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. C.A. Hunter,
    2. R. Kastelein
    . 2012. Interleukin-27: balancing protective and pathological immunity. Immunity. 37:960–969. doi:10.1016/j.immuni.2012.11.003
    OpenUrlCrossRefPubMed
  14. ↵
    1. A.M. Jamieson,
    2. S. Yu,
    3. C.H. Annicelli,
    4. R. Medzhitov
    . 2010. Influenza virus-induced glucocorticoids compromise innate host defense against a secondary bacterial infection. Cell Host Microbe. 7:103–114. doi:10.1016/j.chom.2010.01.010
    OpenUrlCrossRefPubMed
  15. ↵
    1. D. Jankovic,
    2. M.C. Kullberg,
    3. C.G. Feng,
    4. R.S. Goldszmid,
    5. C.M. Collazo,
    6. M. Wilson,
    7. T.A. Wynn,
    8. M. Kamanaka,
    9. R.A. Flavell,
    10. A. Sher
    . 2007. Conventional T-bet+Foxp3− Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J. Exp. Med. 204:273–283. doi:10.1084/jem.20062175
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. D. Jankovic,
    2. D.G. Kugler,
    3. A. Sher
    . 2010. IL-10 production by CD4+ effector T cells: a mechanism for self-regulation. Mucosal Immunol. 3:239–246. doi:10.1038/mi.2010.8
    OpenUrlCrossRefPubMed
  17. ↵
    1. A.C. Liberman,
    2. D. Refojo,
    3. J. Druker,
    4. M. Toscano,
    5. T. Rein,
    6. F. Holsboer,
    7. E. Arzt
    . 2007. The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction. FASEB J. 21:1177–1188. doi:10.1096/fj.06-7452com
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. F. Liu,
    2. J.L. Whitton
    . 2005. Cutting edge: re-evaluating the in vivo cytokine responses of CD8+ T cells during primary and secondary viral infections. J. Immunol. 174:5936–5940.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. M. Löwenberg,
    2. A.P. Verhaar,
    3. G.R. van den Brink,
    4. D.W. Hommes
    . 2007. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol. Med. 13:158–163. doi:10.1016/j.molmed.2007.02.001
    OpenUrlCrossRefPubMed
  20. ↵
    1. G. Lugo-Villarino,
    2. R. Maldonado-Lopez,
    3. R. Possemato,
    4. C. Penaranda,
    5. L.H. Glimcher
    . 2003. T-bet is required for optimal production of IFN-γ and antigen-specific T cell activation by dendritic cells. Proc. Natl. Acad. Sci. USA. 100:7749–7754. doi:10.1073/pnas.1332767100
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. P.R. Mittelstadt,
    2. J.P. Monteiro,
    3. J.D. Ashwell
    . 2012. Thymocyte responsiveness to endogenous glucocorticoids is required for immunological fitness. J. Clin. Invest. 122:2384–2394. doi:10.1172/JCI63067
    OpenUrlCrossRefPubMed
  22. ↵
    1. A.R. Pérez,
    2. S.D. Silva-Barbosa,
    3. L.R. Berbert,
    4. S. Revelli,
    5. J. Beloscar,
    6. W. Savino,
    7. O. Bottasso
    . 2011. Immunoneuroendocrine alterations in patients with progressive forms of chronic Chagas disease. J. Neuroimmunol. 235:84–90. doi:10.1016/j.jneuroim.2011.03.010
    OpenUrlCrossRefPubMed
  23. ↵
    1. D.S. Roos,
    2. R.G. Donald,
    3. N.S. Morrissette,
    4. A.L. Moulton
    . 1994. Molecular tools for genetic dissection of the protozoan parasite Toxoplasma gondii. Methods Cell Biol. 45:27–63. doi:10.1016/S0091-679X(08)61845-2
    OpenUrlCrossRefPubMed
  24. ↵
    1. E.G. Schulz,
    2. L. Mariani,
    3. A. Radbruch,
    4. T. Höfer
    . 2009. Sequential polarization and imprinting of type 1 T helper lymphocytes by interferon-gamma and interleukin-12. Immunity. 30:673–683. doi:10.1016/j.immuni.2009.03.013
    OpenUrlCrossRefPubMed
  25. ↵
    1. R.V. Sionov,
    2. O. Cohen,
    3. S. Kfir,
    4. Y. Zilberman,
    5. E. Yefenof
    . 2006. Role of mitochondrial glucocorticoid receptor in glucocorticoid-induced apoptosis. J. Exp. Med. 203:189–201. doi:10.1084/jem.20050433
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. E.M. Sternberg
    2006. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev. Immunol. 6:318–328. doi:10.1038/nri1810
    OpenUrlCrossRefPubMed
  27. ↵
    1. J. Tian,
    2. W. Qi,
    3. X. Li,
    4. J. He,
    5. P. Jiao,
    6. C. Zhang,
    7. G.Q. Liu,
    8. M. Liao
    . 2012. A single E627K mutation in the PB2 protein of H9N2 avian influenza virus increases virulence by inducing higher glucocorticoids (GCs) level. PLoS ONE. 7:e38233. doi:10.1371/journal.pone.0038233
    OpenUrlCrossRefPubMed
  28. ↵
    1. A. Villarino,
    2. L. Hibbert,
    3. L. Lieberman,
    4. E. Wilson,
    5. T. Mak,
    6. H. Yoshida,
    7. R.A. Kastelein,
    8. C. Saris,
    9. C.A. Hunter
    . 2003. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity. 19:645–655. doi:10.1016/S1074-7613(03)00300-5
    OpenUrlCrossRefPubMed
  29. ↵
    1. S. Wüst,
    2. J. van den Brandt,
    3. D. Tischner,
    4. A. Kleiman,
    5. J.P. Tuckermann,
    6. R. Gold,
    7. F. Lühder,
    8. H.M. Reichardt
    . 2008. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J. Immunol. 180:8434–8443.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. G.S. Yap,
    2. A. Sher
    . 1999. Effector cells of both nonhemopoietic and hemopoietic origin are required for interferon (IFN)-γ– and tumor necrosis factor (TNF)-α–dependent host resistance to the intracellular pathogen, Toxoplasma gondii. J. Exp. Med. 189:1083–1092. doi:10.1084/jem.189.7.1083
    OpenUrlAbstract/FREE Full Text
View Abstract
© 2013 This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
Previous articleNext article
Back to top
Download PDF
Citation Tools
CD4+ T cells are trigger and target of the glucocorticoid response that prevents lethal immunopathology in toxoplasma infection
David G. Kugler, Paul R. Mittelstadt, Jonathan D. Ashwell, Alan Sher, Dragana Jankovic
Journal of Experimental Medicine Sep 2013, 210 (10) 1919-1927; DOI: 10.1084/jem.20122300

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Alerts
Sign In to Email Alerts with your Email Address

Email logo Twitter logo Facebook logo Mendeley logo Reddit logo CiteULike logo LinkedIn logo
The Journal of Experimental Medicine: 216 (2)

Current Issue

February 4, 2019
Volume 216, No. 2

  • Table of Contents
  • All Issues

Jump To

  • Article
    • Abstract
    • RESULTS AND DISCUSSION
    • MATERIALS AND METHODS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info
  • Metrics
  • Preview PDF
 

ARTICLES

  • Current Issue
  • Newest Articles
  • Archive
  • Alerts
  • RSS feeds

FOR AUTHORS

  • Submit a Manuscript
  • Instructions for Authors

ABOUT

  • About JEM
  • Editors & Staff
  • Policies & Permissions
  • Advertise
  • Contact Us
  • Feedback
  • Newsroom
  • Privacy Policy

CONNECT WITH JEM

  • Email
  • Facebook
  • Twitter
  • RSS
  • Instagram

Online ISSN: 1540-9538
Print ISSN: 0022-1007

Copyright © 2019 JEM by Rockefeller University Press